MedPath

B. Riley Upgrades Cognition Therapeutics to Buy Following Positive Lewy Bodies Data

B. Riley analyst Mayank Mamtani has upgraded Cognition Therapeutics (CGTX) from Neutral to Buy, raising the price target to $1.50 from $1, based on the promising results of the Phase 2 SHIMMER study of CT1812 in patients with dementia with Lewy bodies.

B. Riley analyst Mayank Mamtani has upgraded Cognition Therapeutics (CGTX) from Neutral to Buy, raising the price target to $1.50 from $1. This upgrade comes after the company reported topline results from the Phase 2 SHIMMER study of CT1812 in patients with dementia with Lewy bodies, which exceeded expectations in terms of consistency and magnitude of treatment effect. Mamtani highlighted in a research note that these results indicate Cognition Therapeutics is not only here to stay but is poised to thrive. The positive outcomes from the SHIMMER study underscore the potential of CT1812 as a significant treatment option for dementia with Lewy bodies, marking a pivotal moment for Cognition Therapeutics in the field of clinical trial medical treatment.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Structure Therapeutics Earns Buy Rating for Innovative Oral Obesity Treatments

Structure Therapeutics, Inc. has been awarded a Buy rating by Stifel Nicolaus analyst Annabel Samimy, thanks to its innovative oral small molecule treatments for obesity. The company's lead candidate, GSBR-1290, has shown promising early trial results, indicating potential for widespread use in primary care settings. Despite challenges, the company's strategic approach and diversified pipeline support the positive outlook.

Cognition Therapeutics Price Target Increased by H.C. Wainwright

H.C. Wainwright has raised its price target for Cognition Therapeutics from $5 to $6, maintaining a Buy rating, following positive Phase 2 SHIMMER trial results for CT1812 in treating dementia with Lewy bodies.

Cardiol Therapeutics' CardiolRx Shows Sustained Efficacy in Recurrent Pericarditis, Poised for Phase III Trials

Cardiol Therapeutics' CardiolRx demonstrated sustained pain relief in recurrent pericarditis patients over six months, with average pain scores decreasing from 5.8 to 1.5.
The MAvERIC trial data suggests CardiolRx performs favorably compared to rilonacept in pain reduction and CRP level normalization.

PTC Therapeutics Receives Buy Ratings Following FDA Approval of Gene Therapy Kebilidi

PTC Therapeutics received a Buy rating from William Blair analyst Sami Corwin due to the FDA approval of Kebilidi, a gene therapy for AADC deficiency.
Kebilidi is the first gene therapy administered directly to the brain, holding a broad label for treating a wide range of patients with AADC deficiency.

Altimmune's Pemvidutide Shows Promise in Obesity Treatment with Strategic Phase III Development

Altimmune's pemvidutide advances to Phase III obesity program following successful FDA meeting, incorporating an innovative design targeting diverse patient subpopulations.
The FDA has agreed on pemvidutide's safety profile, negating the need for extensive safety studies and highlighting its favorable cardiac efficacy compared to competitors.

Cognition Therapeutics' CT1812 Shows Promise in Phase 2 Trials for Alzheimer's and Lewy Body Dementia

Cognition Therapeutics' CT1812 demonstrated a 95% slowing of cognitive decline in Alzheimer's patients with lower plasma p-tau217 levels in Phase 2 SHINE study.
The Phase 2 SHIMMER study of CT1812 in dementia with Lewy bodies (DLB) met its primary endpoint of safety and tolerability.

Intellia Therapeutics Prioritizes Late-Stage Programs Following Promising Gene Editing Data

Intellia Therapeutics is focusing on advancing pivotal studies for ATTR and HAE, signaling a strategic prioritization of late-stage clinical programs.
Phase II trial results for NTLA-2002 in hereditary angioedema (HAE) showed a 77% reduction in attacks with the 50 mg dose over 16 weeks.

Viridian Therapeutics' Veligrotug Shows Promise in Phase III Thyroid Eye Disease Trial

Viridian Therapeutics' VRDN-001 (veligrotug) demonstrated satisfactory efficacy and safety in a Phase III THRIVE study for thyroid eye disease (TED).
The trial results suggest veligrotug could gain a moderate market share from Tepezza, with potential annual sales between $500 million and $700 million.

Bioxcel Therapeutics Gains Analyst Confidence with Agitation Treatment Advancements

H.C. Wainwright reiterated a Buy rating for Bioxcel Therapeutics (BTAI), citing the Phase 3 trial of BXCL501 for agitation in bipolar disorder and schizophrenia.
The SERENITY At-Home trial's progress and potential for top-line results in H2 2025 could significantly increase the company's value.

Kymera Therapeutics Shares Price Target Rises on Positive Development

H.C. Wainwright has raised Kymera Therapeutics' stock price target to $60, citing Sanofi's decision to expand Phase 2 trials for Hidradenitis Suppurativa and Atopic Dermatitis. This move is seen as a positive development for Kymera, with the potential success of its KT-474 program influencing the decision.

Reference News

[1]
B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data
finance.yahoo.com · Dec 20, 2024

B. Riley analyst Mayank Mamtani upgraded Cognition Therapeutics (CGTX) to Buy, raising the price target to $1.50 from $1...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy